HealthQuill Pharma
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.
Pharma

AstraZeneca to invest $2.5 Billion in Beijing R&D hub, expands China presence

HQ Team March 21, 2025: AstraZeneca has announced a $2.5 billion investment in a new Beijing R&D center, partnerships with Harbour BioMed and.

Read More
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Pharma

AstraZeneca acquires EsoBiotec for $1billion in a bid to push its cell therapy agenda

HQ Team March 17, 2025: AstraZeneca has announced plans to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies, for up to.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Pharma

Gilead’s once-yearly lenacapavir shot for HIV prevention shows strong promise

HQ Team March 12, 2025: In a significant development for HIV prevention, Gilead Sciences has unveiled promising data from its Phase 1 study.

Read More
Roche and Zealnd pharma go in for a $5.3billion deal for obesity candidate
Pharma

Roche secures Zealand pharma’s obesity drug in $5.3 billion deal

HQ Team March 12, 2025: Swiss pharmaceutical giant Roche has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma to.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More
Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s technology to discover tissue-targeting molecules.
Drugs Medical Pharma

Novo Nordisk to pay US-based Gensaic $354 million upfront in licensing deal

HQ Team March 5, 2025: Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s.

Read More
Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer's disease, and these abnormal proteins also accumulate in the dying cells in the retina of the eyes of the patients with the condition, investigators at Cedars-Sinai Medical Center found.
Health Pharma Research

Abnormal protein accumulation in patient’s eyes linked to Alzheimer’s

HQ Team March 4, 2025: Tau proteins in brain neurons can form neurofibrillary tangles, which are a hallmark of Alzheimer’s disease, and these.

Read More
AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.
Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

 HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

Read More
Thermo Fisher Scientific to buy Solvemtum’s purification unit for $4.1 billion in cash
Drugs Medical Pharma

Thermo Fisher to buy Solventum’s filtration unit for $4.1 billion in cash

HQ Team March 1, 2025: Thermo Fisher Scientific Inc., will buy Solventum’s purification and filtration business for $4.1 billion in cash to support.

Read More
Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according to a statement.
Drugs Medical Pharma

Eli Lilly to set up four manufacturing facilities in US for $27 billion

Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according.

Read More